Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Mark on +44 1494 818 049 or markd@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
markd@zenopa.com
+44 1494 818 049

Testimonials
I have say that Zenopa were extremely professional and were a thorough consultancy to work with and I was always impressed with their attention to detail.
Mark, 2013

Amgen to receive priority review of new cancer treatment

19 July 2010 00:00 in Pharmaceutical Company Product News


Amgen is to be granted priority review status from an industry regulatory body for denosumab, a treatment designed to reduce skeletal related events in patients with cancer.

The US Food and Drug Administration has allocated the status to Amgen's treatment based on data from a number of phase III studies, which illustrate the drug's benefits compared to Zometa.

This US submission is one of a number of regulatory applications currently pending for the drug, with Amgen having also submitted denosumab for approval in the EU, Australia, Canada and Switzerland.

Dr Roger Perlmutter, the company's executive vice-president of research and development, said the priority review designation illustrates the potential for the drug to represent a "meaningful advance" over the current standard of care.

He added: "In clinical trials, denosumab has consistently demonstrated an ability to reduce the burden of complications from skeletal metastases, with a positive benefit-risk profile."

Last week, Amgen announced the appointment of Jonathan Peacock as its new executive vice-president and chief financial officer.

Other news stories from 19/07/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd